Trinity Bio ADR (TRIB) Stock Price, Quote & News

Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles,...

Industry: Medical Devices

Sector: Healthcare

Phone: 353 1 276 9800

Fax: 353 1 276 9888

Website: www.trinitybiotech.com

Address:

IDA Business Park, Bray, Ireland

kd1313 Nov. 14 at 8:01 PM

$TRIB Perceptive got about 95 million in stock. It’s close to the amount they are owed. Perceptive knows the CGM deal isn’t going well so instead of TRIB defaulting on the loan, perceptive will take what they can from the shares, and because its stock they can write off the loss. I’m guessing they only are able to exit 30-40% of what they put into the deal. Then comes the R/S.

0 · Reply

kd1313 Nov. 14 at 7:58 PM

$TRIB low volume means little to no interest in the stock. So sad.

0 · Reply

Think_Bigly Nov. 14 at 4:47 PM

$TRIB historically, S5 has been wrong 95%

0 · Reply

Think_Bigly Nov. 14 at 4:44 PM

$TRIB @realDonaldTrump to announce an Execute Order BANNING spoofing, naked shorting, etc. with the most SEVERE punishments imaginable.

0 · Reply

kd1313 Nov. 14 at 6:43 AM

$TRIB .85

0 · Reply

Super5Investments Nov. 14 at 3:09 AM

$TRIB historically this has been garbage.

0 · Reply

Think_Bigly Nov. 13 at 8:37 PM

$TRIB ER next Thursday?

0 · Reply

deepthinker Nov. 13 at 6:30 PM

$TRIB I mean, I don’t want to be a pessimist, but it looked like everything was ready to go three weeks ago. What happened?

0 · Reply

kd1313 Nov. 13 at 4:39 PM

$TRIB @m1ster_leboeuf you must be mad that I was right. Dilution continues, SP falls, nothing positive in sight.

1 · Reply

kd1313 Nov. 12 at 7:28 PM

$TRIB game over. Told you. The slow bleed to .50 coming

1 · Reply

Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test

Oct 27, 2025, 9:00 AM EDT - 18 days ago

Trinity Biotech Welcomes Perceptive Advisor's Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth

Sep 2, 2025, 9:30 AM EDT - 2 months ago

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements

Aug 21, 2025, 9:00 AM EDT - 3 months ago

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

Aug 20, 2025, 9:00 AM EDT - 3 months ago

Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation

Aug 14, 2025, 9:00 AM EDT - 3 months ago

Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service

Aug 12, 2025, 8:45 AM EDT - 3 months ago

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

Aug 7, 2025, 8:00 AM EDT - 3 months ago

Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service

Jul 24, 2025, 8:20 AM EDT - 4 months ago

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market

Jul 1, 2025, 9:00 AM EDT - 4 months ago

Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround

Jun 24, 2025, 8:00 AM EDT - 5 months ago

Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation

May 15, 2025, 4:00 PM EDT - 6 months ago

Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

Mar 14, 2025, 4:30 PM EDT - 8 months ago

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

Mar 13, 2025, 7:30 AM EDT - 8 months ago

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

Feb 28, 2025, 8:30 AM EST - 9 months ago

Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology

Feb 6, 2025, 7:30 AM EST - 10 months ago

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial

Jan 28, 2025, 7:20 AM EST - 10 months ago

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology

Dec 24, 2024, 8:33 AM EST - 11 months ago

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

Dec 18, 2024, 11:00 AM EST - 11 months ago

Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV

Nov 15, 2024, 12:37 PM EST - 1 year ago

Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript

Nov 15, 2024, 9:00 AM EST - 1 year ago

Trinity Biotech Announces Q3 2024 Financial Results

Nov 14, 2024, 8:07 AM EST - 1 year ago

Trinity Biotech to Announce Q3 2024 Financial Results

Oct 25, 2024, 8:45 AM EDT - 1 year ago

Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform

Oct 25, 2024, 8:45 AM EDT - 1 year ago

Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture

Oct 7, 2024, 8:15 AM EDT - 1 year ago

Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

Sep 24, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology

Sep 3, 2024, 9:55 AM EDT - 1 year ago

Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales

Aug 20, 2024, 5:00 PM EDT - 1 year ago

Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director

Aug 16, 2024, 3:43 AM EDT - 1 year ago

Trinity Biotech plc (TRIB) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Trinity Biotech Announces Q2 2024 Financial Results

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech to Announce Q2 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements

Aug 2, 2024, 9:24 AM EDT - 1 year ago

Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience

Jul 9, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Announces Appointment of A New CFO

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor

Jun 10, 2024, 9:10 AM EDT - 1 year ago

Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association

Jun 3, 2024, 4:00 AM EDT - 1 year ago

Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology

May 23, 2024, 6:44 PM EDT - 1 year ago

Trinity Biotech plc (TRIB) Q1 2024 Earnings Call Transcript

May 23, 2024, 8:00 AM EDT - 1 year ago

Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance

May 21, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech plc to Announce Q1 2024 Financial Results

May 16, 2024, 9:18 AM EDT - 1 year ago

Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI

May 13, 2024, 11:42 AM EDT - 1 year ago

Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales

May 8, 2024, 10:36 AM EDT - 1 year ago

Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Apr 4, 2024, 3:03 PM EDT - 1 year ago

Trinity Biotech plc (TRIB) Q4 2023 Earnings Call Transcript

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates

Mar 28, 2024, 6:39 PM EDT - 1 year ago

Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results

Mar 8, 2024, 10:03 AM EST - 1 year ago

Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

kd1313 Nov. 14 at 8:01 PM

0 · Reply

kd1313 Nov. 14 at 7:58 PM

$TRIB low volume means little to no interest in the stock. So sad.

0 · Reply

Think_Bigly Nov. 14 at 4:47 PM

$TRIB historically, S5 has been wrong 95%

0 · Reply

Think_Bigly Nov. 14 at 4:44 PM

$TRIB @realDonaldTrump to announce an Execute Order BANNING spoofing, naked shorting, etc. with the most SEVERE punishments imaginable.

0 · Reply

kd1313 Nov. 14 at 6:43 AM

$TRIB .85

0 · Reply

Super5Investments Nov. 14 at 3:09 AM

$TRIB historically this has been garbage.

0 · Reply

Think_Bigly Nov. 13 at 8:37 PM

$TRIB ER next Thursday?

0 · Reply

deepthinker Nov. 13 at 6:30 PM

$TRIB I mean, I don’t want to be a pessimist, but it looked like everything was ready to go three weeks ago. What happened?

0 · Reply

kd1313 Nov. 13 at 4:39 PM

$TRIB @m1ster_leboeuf you must be mad that I was right. Dilution continues, SP falls, nothing positive in sight.

1 · Reply

kd1313 Nov. 12 at 7:28 PM

$TRIB game over. Told you. The slow bleed to .50 coming

1 · Reply

deepthinker Nov. 11 at 8:08 PM

$TRIB I’m guessing this multi-part deal is very complex and has had many obstacles to overcome. Let’s hope it crosses the finish line.

0 · Reply

kd1313 Nov. 11 at 3:07 PM

$TRIB absolute trash stock. Dilution at its best.

1 · Reply

Clydagh Nov. 11 at 12:21 PM

$TRIB finally took the trouble to read the Perceptive filing. They have not bought any new shares or exercised any warrants - the news story is incorrect. The filing is a proposal to reduce certain amounts TRIB owe Perceptive in return for new shares. The ultimate motive is possibly to make it easier for TRIB to raise fresh cash from new investors - although this is not stated. Proposal is for Perceptive to take new shares in lieu of 1. $5M cash payment due this month 2. Half share of CGM Partner downpayment 3. Some existing debt None of that puts any new money into TRIB and they are very short of cash although Q3 may finally be cash positive. Still they have heavy CGM related R&D spend coming up. 2. above stand out for me - if a CGM partner deal happens soon TRIB get to keep all the cash from any downpayment. Another possibility is they are making it easier to do a rights issue. New investors wont see their cash fly straight out the door again to Perceptive (that $5M due now, etc).

1 · Reply

BullJack Nov. 7 at 6:47 AM

$TRIB wow Perceptive Advisors bought. 100,442,000 shares of Trinity Biotech PLC at a trade price of $0.9463 per share. Almost a $100M equity investment by a major biotech fund

0 · Reply

Think_Bigly Nov. 5 at 7:59 PM

$TRIB Bundle of 5+ Tests @ 4M market size. DD on price $100-185/test. 10% of market =$50M/yr -The PLA code allows the clinical lab or manufacturer to preferentially differentiate the test in terms of payor pricing and **avoid the utilization of multiple generic lower value CPT codes, ultimately incentivising Immco Diagnostic’s commercial partners to provide broader patient access to this key diagnostic tool. https://sjogrens.org/understanding-sjogrens/diagnosis

0 · Reply

Think_Bigly Nov. 5 at 2:57 PM

$TRIB The Immco Sjögren’s Diagnostic Test Panel analyzes and identifies the most comprehensive set of biomarkers for advanced autoimmune dry eye and early detection of Sjögren’s syndrome. Dry eyes may indicate a serious health issue — including Sjögren’s syndrome. Sjögren’s syndrome in its earliest stages commonly presents as routine dry eye. Sjögren’s syndrome affects up to 4 million people in the U.S., with many undiagnosed. Sjögren’s syndrome is a serious autoimmune disease that causes damage to the exocrine glands, which are responsible for producing moisture 3 .. Early diagnosis can result in patients being monitored for organ-specific manifestations, general symptoms, associated autoimmune diseases and malignancies. https://trinitybiotech.com/reference-lab-services/sjo-diagnostic-test/

0 · Reply

2020focus Nov. 4 at 3:25 PM

$TRIB I'm curious for those checking in on this stock whether earnings through Sept will be reported by Nov 14 or 21? What should we expect?

1 · Reply

Think_Bigly Nov. 3 at 4:13 AM

$NUKK I’m out. Good luck all!! I decided to make the move to $TRIB

1 · Reply

kd1313 Oct. 31 at 5:47 PM

$TRIB let the dilution begin. Perceptive will get what they can from the shares and shortly after the reverse split will come.

1 · Reply

kd1313 Oct. 31 at 5:46 PM

$TRIB Perceptive Advisors LLC executed a notable transaction by acquiring 100,442,000 shares of Trinity Biotech PLC at a trade price of $0.9463 per share. This acquisition has resulted in a 3.4% impact on the firm's portfolio. The transaction increased Perceptive Advisors LLC's total holdings in Trinity Biotech PLC to 100,800,000 shares, which now represents 22.50%

0 · Reply

Clydagh Oct. 31 at 11:24 AM

$TRIB this looks like a warrant exercise - one way of putting some cash in; https://www.gurufocus.com/news/3173885/perceptive-advisors-llc-acquires-significant-stake-in-trinity-biotech-plc?mobile=true News must be imminent

1 · Reply

RiccoTheGreat2 Oct. 30 at 7:20 PM

$TRIB I’m out. Good luck all!! I decided to make the move to $NUKK

1 · Reply

Market Cap	3.06M
Revenue (ttm)	61.56M
Net Income (ttm)	-31.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-51.64%
Debt to Equity Ratio	-1.82

Volume	37,400
Avg Vol	111,804
Day's Range	N/A - N/A
Shares Out	3.59M
Stochastic %K	21%
Beta	N/A
Analysts	Hold
Price Target	$15.00